Our top pick for
PerkinElmer, Inc is a diagnostics & research business based in the US. PerkinElmer shares (PKI) are listed on the NYSE and all prices are listed in US Dollars. PerkinElmer employs 13,000 staff and has a trailing 12-month revenue of around USD$3 billion.
Since the stock market crash in March caused by coronavirus, PerkinElmer's share price has had significant positive movement.
Its last market close was USD$124.02, which is 25.13% up on its pre-crash value of USD$92.85 and 97.14% up on the lowest point reached during the March crash when the shares fell as low as USD$62.91.
If you had bought USD$1,000 worth of PerkinElmer shares at the start of February 2020, those shares would have been worth USD$730.74 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,335.70.
|Latest market close||USD$124.02|
|52-week range||USD$62.91 - USD$134.39|
|50-day moving average||USD$121.1791|
|200-day moving average||USD$105.8512|
|Wall St. target price||USD$128.86|
|Dividend yield||USD$0.28 (0.23%)|
|Earnings per share (TTM)||USD$2.628|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-17)||-6.75%|
|1 month (2020-10-27)||-2.41%|
|3 months (2020-08-27)||8.31%|
|6 months (2020-05-23)||N/A|
|1 year (2019-11-23)||N/A|
|2 years (2018-11-23)||51.86%|
|3 years (2017-11-24)||69.06%|
|5 years (2015-11-24)||136.05%|
Valuing PerkinElmer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PerkinElmer's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PerkinElmer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 47x. In other words, PerkinElmer shares trade at around 47x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
PerkinElmer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4449. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into PerkinElmer's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
PerkinElmer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$688.4 million.
The EBITDA is a measure of a PerkinElmer's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$3 billion|
|Operating margin TTM||15.39%|
|Gross profit TTM||USD$1.4 billion|
|Return on assets TTM||4.39%|
|Return on equity TTM||10.37%|
|Market capitalisation||USD$13.8 billion|
TTM: trailing 12 months
There are currently 2.8 million PerkinElmer shares held short by investors – that's known as PerkinElmer's "short interest". This figure is 11.2% up from 2.6 million last month.
There are a few different ways that this level of interest in shorting PerkinElmer shares can be evaluated.
PerkinElmer's "short interest ratio" (SIR) is the quantity of PerkinElmer shares currently shorted divided by the average quantity of PerkinElmer shares traded daily (recently around 766397.57412399). PerkinElmer's SIR currently stands at 3.71. In other words for every 100,000 PerkinElmer shares traded daily on the market, roughly 3710 shares are currently held short.
However PerkinElmer's short interest can also be evaluated against the total number of PerkinElmer shares, or, against the total number of tradable PerkinElmer shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PerkinElmer's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 PerkinElmer shares in existence, roughly 30 shares are currently held short) or 0.0516% of the tradable shares (for every 100,000 tradable PerkinElmer shares, roughly 52 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against PerkinElmer.
Find out more about how you can short PerkinElmer stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like PerkinElmer.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 21.66
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and PerkinElmer's overall score of 21.66 (as at 10/01/2020) is pretty good – landing it in it in the 25th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like PerkinElmer is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.15/100
PerkinElmer's environmental score of 3.15 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that PerkinElmer is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 12.09/100
PerkinElmer's social score of 12.09 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that PerkinElmer is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 9.42/100
PerkinElmer's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that PerkinElmer is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. PerkinElmer scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that PerkinElmer has, for the most part, managed to keep its nose clean.
|Total ESG score||21.66|
|Total ESG percentile||24.92|
|Environmental score percentile||4|
|Social score percentile||4|
|Governance score percentile||4|
|Level of controversy||2|
Dividend payout ratio: 6.02% of net profits
Recently PerkinElmer has paid out, on average, around 6.02% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.23% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), PerkinElmer shareholders could enjoy a 0.23% return on their shares, in the form of dividend payments. In PerkinElmer's case, that would currently equate to about $0.28 per share.
While PerkinElmer's payout ratio might seem low, this can signify that PerkinElmer is investing more in its future growth.
PerkinElmer's most recent dividend payout was on 6 November 2020. The latest dividend was paid out to all shareholders who bought their shares by 15 October 2020 (the "ex-dividend date").
PerkinElmer's shares were split on a 2:1 basis on 4 June 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your PerkinElmer shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for PerkinElmer shares which in turn could have impacted PerkinElmer's share price.
Over the last 12 months, PerkinElmer's shares have ranged in value from as little as $62.91 up to $134.39. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while PerkinElmer's is 1.3006. This would suggest that PerkinElmer's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophym, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.